Tags

Type your tag names separated by a space and hit enter

Cystatin C as a marker of early changes of renal function in Fabry nephropathy.
J Nephrol. 2007 Jul-Aug; 20(4):437-43.JN

Abstract

BACKGROUND

A sensitive, feasible and reproducible marker for renal function is necessary to evaluate the clinical efficacy of enzyme replacement therapy (ERT) in Fabry nephropathy. Serum creatinine has some limitations and cystatin C has been proposed, in other nephropathies, as a useful marker of renal function. The use of cystatin C as a marker of glomerular filtration rate (GFR) was investigated in Fabry patients receiving ERT.

METHODS

Renal function was evaluated with serum creatinine, serum cystatin C and estimated GFR (through Modification of Diet in Renal Disease [MDRD], Cockcroft-Gault [C&G] and Hoek formulae) in 21 Fabry patients receiving ERT with agalsidase alfa for 3 years and in 13 Fabry patients receiving agalsidase alfa for 4 years.

RESULTS

During years of ERT while serum creatinine remained stable, cystatin C values showed a significant, increasing trend right from the first year of ERT.

CONCLUSIONS

In Fabry disease, cystatin C is a sensitive and reliable marker of renal function, and it should be taken into account when evaluating GFR trends during ERT.

Authors+Show Affiliations

Nephrology and Dialysis Unit, Ospedale Belcolle, Viterbo, Italy. sandro.feriozzi@tiscali.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

17879210

Citation

Feriozzi, Sandro, et al. "Cystatin C as a Marker of Early Changes of Renal Function in Fabry Nephropathy." Journal of Nephrology, vol. 20, no. 4, 2007, pp. 437-43.
Feriozzi S, Germain DP, Di Vito R, et al. Cystatin C as a marker of early changes of renal function in Fabry nephropathy. J Nephrol. 2007;20(4):437-43.
Feriozzi, S., Germain, D. P., Di Vito, R., Legrand, A., Ricci, R., & Barbey, F. (2007). Cystatin C as a marker of early changes of renal function in Fabry nephropathy. Journal of Nephrology, 20(4), 437-43.
Feriozzi S, et al. Cystatin C as a Marker of Early Changes of Renal Function in Fabry Nephropathy. J Nephrol. 2007 Jul-Aug;20(4):437-43. PubMed PMID: 17879210.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cystatin C as a marker of early changes of renal function in Fabry nephropathy. AU - Feriozzi,Sandro, AU - Germain,Dominique P, AU - Di Vito,Raffaele, AU - Legrand,Alain, AU - Ricci,Roberta, AU - Barbey,Frédéric, PY - 2007/9/20/pubmed PY - 2008/1/23/medline PY - 2007/9/20/entrez SP - 437 EP - 43 JF - Journal of nephrology JO - J Nephrol VL - 20 IS - 4 N2 - BACKGROUND: A sensitive, feasible and reproducible marker for renal function is necessary to evaluate the clinical efficacy of enzyme replacement therapy (ERT) in Fabry nephropathy. Serum creatinine has some limitations and cystatin C has been proposed, in other nephropathies, as a useful marker of renal function. The use of cystatin C as a marker of glomerular filtration rate (GFR) was investigated in Fabry patients receiving ERT. METHODS: Renal function was evaluated with serum creatinine, serum cystatin C and estimated GFR (through Modification of Diet in Renal Disease [MDRD], Cockcroft-Gault [C&G] and Hoek formulae) in 21 Fabry patients receiving ERT with agalsidase alfa for 3 years and in 13 Fabry patients receiving agalsidase alfa for 4 years. RESULTS: During years of ERT while serum creatinine remained stable, cystatin C values showed a significant, increasing trend right from the first year of ERT. CONCLUSIONS: In Fabry disease, cystatin C is a sensitive and reliable marker of renal function, and it should be taken into account when evaluating GFR trends during ERT. SN - 1121-8428 UR - https://www.unboundmedicine.com/medline/citation/17879210/Cystatin_C_as_a_marker_of_early_changes_of_renal_function_in_Fabry_nephropathy_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=17879210.ui DB - PRIME DP - Unbound Medicine ER -